HPTN 084

A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women 


PrEP may only reach its full potential for HIV prevention with agents that do not depend on daily or near-daily pill-taking. The development of alternative agents for PrEP, and/or more adherence-friendly schedules for currently available agents, could increase prevention choices and increase acceptability. Long-acting injectable agents have the potential to prevent HIV acquisition without relying on adherence to a daily oral regimen.


  • Dr Carrie-Anne Mathew (Co-Principal Investigator)
  • Dr Elizabeth Roos (Co-Principal Investigator)
  • Prof Sinead Delany-Moretlwe (Sub Investigators)
  • Dr Monique Da Fonseca (Sub Investigators)
  • Dr Juliet Vimbai Rundogo (Sub Investigators)
  • Dr Nicole Poovan (Sub Investigators)

Latest Update

April 2024

For more details about HPTN 084 please email

Click here for further details regarding the HPTN 084 study.

Research and Policy Briefs

HPTN 084

Stay up to date

Get updates on news, resources, events and happenings from Wits RHI.